| Name | L-Kynurenine |
| Description | L-Kynurenine ((S)-Kynurenine) is an endogenous agonist of the tryptophan metabolite and the aromatic hydrocarbon receptor (AHR). L-Kynurenine can inhibit the proliferation of allogeneic T cells and increase the invasion of malignant U87 glioma cells into the collagen matrix. |
| In vitro | METHODS: Human corneal endothelial cells (HCEC) were treated with L-Kynurenine (10-40 µM), and apoptosis of HCECs was evaluated by flow cytometry using fluorescent isothiocyanate Annexin-V conjugates (FITC).
RESULTS: L-Kynurenine-induced apoptosis slightly increased. [1]
METHODS: NK92 MI cells were treated with L-Kynurenine (0-800 μM) for 72 hours. Cell viability was evaluated by trypan blue staining, and flow cytometry analysis or functional detection was performed.
RESULTS: L-Kynurenine dose-dependently induced cell growth inhibition and apoptosis. [2] |
| In vivo | METHODS: To study the effect of L-Kynurenine on arteries, L-Kynurenine was administered to the mesenteric arteries (0.3 mM to 1 mM) and aorta (1 mM to 1 mM) of male Wistar rats.
RESULTS: L-Kynurenine induced concentration-dependent diastolic responses in the mesenteric arteries and aorta of rats, while the selective Kv7 inhibitor aspirin and the depolarizing agent potassium chloride eliminated this diastolic effect. [3]
METHODS: To study the neuroprotective effect of L-Kynurenine, L-Kynurenine (50-300 mg/kg) was intraperitoneally injected into neonatal rats. One hour after intraperitoneal injection, the young rats were exposed to a hypoxic environment for 1.5 hours to construct a hypoxia-ischemia neonatal rat model. L-Kynurenine (100, 200, 3000, 400 mg/kg) was intraperitoneally injected into neonatal rats. One hour after intraperitoneal injection, NMDA was injected to construct the neonatal rat model of NMDA injury.
RESULTS: L-Kynurenine demonstrated a dose-dependent significant neuroprotective effect and had a complete protective effect at a dose of 300 mg/kg. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (240.14 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 1 mg/mL (4.8 mM), Sonication is recommended.
H2O : 4 mg/mL (19.21 mM), Sonication is recommended.
|
| Keywords | L-Kynurenine | LKynurenine | L Kynurenine | Kynurenine | Inhibitor | inhibit | Human Endogenous Metabolite | EndogenousMetabolite | Endogenous Metabolite | ArylHydrocarbonReceptor | Aryl Hydrocarbon Receptor | AhR |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Formamide | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Natural Product Library | Microbial Natural Product Library | Natural Product Library for HTS | Immunology/Inflammation Compound Library | Human Endogenous Metabolite Library | Bioactive Compounds Library Max | Gut Microbial Metabolite Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
